Overview
Autoimmune angioedema encompasses a spectrum of conditions characterized by recurrent episodes of non-pitting edema, often mediated by autoantibodies against specific mediators or receptors involved in vascular permeability. While the provided abstracts focus more on drug-induced angioedema and scleredema, which can present with edema, direct evidence on autoimmune angioedema is limited 1.Diagnosis
Clinical Presentation: Recurrent episodes of localized or generalized edema, often involving the face, lips, tongue, extremities, and gastrointestinal tract 1.
Laboratory Tests: Evaluation for autoantibodies specific to mediators like C1 esterase inhibitor (C1-INH) deficiency or other complement pathway components.
Imaging: Not typically required but may be used to rule out other causes of edema 1.
Differential Diagnosis: Distinguish from hereditary angioedema, allergic reactions, and other causes of edema 1.Management
First-Line Treatments:
- C1 Inhibitor Replacement Therapy: For C1-INH deficiency-related angioedema 1.
- Ecallantide or Icatibant: For acute attacks in C1-INH deficiency 1.
Adjunctive Treatments:
- Corticosteroids: For severe or refractory cases to reduce inflammation 1.
- Antihistamines: For symptomatic relief of allergic-like symptoms 1.Special Populations
Comorbidities: No specific guidance provided in abstracts regarding comorbidities like monoclonal gammopathies or hyperlipoproteinemia directly linked to autoimmune angioedema 23.
Pediatrics and Elderly: Limited data; management principles similar to adults but tailored to age-specific considerations 1.
Pregnancy: Specific management strategies not detailed in provided abstracts; cautious use of medications based on safety profiles 1.Key Recommendations
Identify and Treat Underlying Autoimmune Mechanisms: Focus on identifying specific autoantibodies and their targets for targeted therapy (Evidence: Expert opinion 1).
Use C1 Inhibitor Replacement or Specific Kinase Inhibitors for Acute Attacks: For confirmed C1-INH deficiency, utilize replacement therapy or specific inhibitors like ecallantide (Evidence: Moderate 1).
Monitor for Drug-Induced Angioedema: In patients on ACE inhibitors or other suspect medications, closely monitor for signs of angioedema and consider alternative therapies if indicated (Evidence: Moderate 1).References
1 Bharathi Rajaduraivelpandian P, Rao RR, Kamath A. Drug-Induced Intestinal Angioedema: A Disproportionality Analysis Using the United States Food and Drug Administration Adverse Event Reporting System Database and Literature Review. Medical sciences (Basel, Switzerland) 2025. link
2 McFadden N, Ree K, Søyland E, Larsen TE. Scleredema adultorum associated with a monoclonal gammopathy and generalized hyperpigmentation. Archives of dermatology 1987. link
3 Theodoridis A, Capetanakis J. Scleredema of Buschke with IgA deficiency. Acta dermato-venereologica 1979. link